BIOS — Biosenic SA Share Price
0.000.00%
Last trade - 00:00- €1.18m
- €26.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -123.95% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | 1 | 1 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biosenic SA formerly known as Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. It also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).
Directors
- Baron Stephenne CHM (71)
- Miguel Forte CEO (60)
- Lieve Creten CFO
- Benoit Moreaux CTO (47)
- Anthony Ting CSO
- Jean-Luc Vandebroek EDR (48)
- Olivier Godeaux OTH (57)
- Anne Leselbaum OTH
- Stefanos Theoharis OTH
- Claudia D'Augusta IND
- Damian Marron IND (47)
- Gloria Matthews IND (48)
- Jean-Paul Prieels IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 22nd, 2006
- Public Since
- February 6th, 2015
- No. of Employees
- 11
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 652,862,279
- Address
- Rue Granbonpre 11, Batiment H (bte 24), MONT-SAINT-GUIBERT, 1435
- Web
- https://www.bonetherapeutics.com/
- Phone
- +32 493097366
- Auditors
- BDO Bedrijfsrevisoren – Réviseurs d’entreprises SRL
Upcoming Events for BIOS
Q1 2025 Biosenic SA Earnings Release
Biosenic SA Annual Shareholders Meeting
Similar to BIOS
Fagron NV
Euronext - Brussels
Hyloris Pharmaceuticals SA
Euronext - Brussels
Financiere de Tubize SA
Euronext - Brussels
UCB SA
Euronext - Brussels
FAQ
What is the Biosenic SA share price?
As of Today at 19:37 UTC, shares in Biosenic SA are trading at €0.00. This share price information is delayed by 15 minutes.
How has the Biosenic SA share price performed this year?
Shares in Biosenic SA last closed at €0.00 and the price had moved by -91.09% over the past 365 days. In terms of relative price strength the Biosenic SA share price has underperformed the FTSE Global All Cap Index by -91.25% over the past year.
What are the analyst and broker recommendations for Biosenic SA?
The overall consensus recommendation for Biosenic SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Biosenic SA dividend yield?
Biosenic SA does not currently pay a dividend.
Does Biosenic SA pay a dividend?
Biosenic SA does not currently pay a dividend.
When does Biosenic SA next pay dividends?
Biosenic SA does not currently pay a dividend.
How do I buy Biosenic SA shares?
To buy shares in Biosenic SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biosenic SA?
As of the previous close price of €0.00, shares in Biosenic SA had a market capitalisation of €1.18m.
Where are Biosenic SA shares listed?
Here are the trading details for Biosenic SA:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: BIOS
What kind of share is Biosenic SA?
Based on an overall assessment of its quality, value and momentum Biosenic SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biosenic SA share price forecast for 2025?
The analyst consensus target price for shares in Biosenic SA is €0.10. That is 5455.56% above the last closing price of €0.00.
Analysts covering Biosenic SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.05 for the next financial year.
Find out moreWhat is the trend in the Biosenic SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosenic SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -72.44%.
As of the last closing price of €0.00, shares in Biosenic SA were trading -72.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biosenic SA PE Ratio?
The Biosenic SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biosenic SA?
Biosenic SA's management team is headed by:
- Baron Stephenne - CHM
- Miguel Forte - CEO
- Lieve Creten - CFO
- Benoit Moreaux - CTO
- Anthony Ting - CSO
- Jean-Luc Vandebroek - EDR
- Olivier Godeaux - OTH
- Anne Leselbaum - OTH
- Stefanos Theoharis - OTH
- Claudia D'Augusta - IND
- Damian Marron - IND
- Gloria Matthews - IND
- Jean-Paul Prieels - IND